neoag
Neoantigen × AI
Daily research signal
TOPICS / TUMOR TYPE

Ovarian cancer

Ovarian cancer — a setting for neoantigen and shared-antigen vaccine strategies.

Topic9 items2026-07-25 – 2026-10-17
Tumor types
Melanoma88Head & neck cancer10Liver cancer (HCC)10Ovarian cancer9Glioblastoma8Colorectal cancer5Pancreatic cancer5Breast cancer3Lung cancer (NSCLC)2Lynch syndrome2Kidney cancer (RCC)2Gastric cancer1
01
Clinical

Dana-Farber’s personalized cancer vaccine NeoVax shows immune activity in ovarian cancer trial - AllSci

Dana-Farber's personalized cancer vaccine NeoVax showed immune activity in an ovarian cancer trial, per the report. The item provides headline-level detail only, but the signal matters because it extends the personalized vaccine approach beyond melanoma, where today's clinical activity is concentrated, into ovarian cancer. Full data disclosure will be needed to judge whether immune activity translates into clinical benefit.

Melanoma
news · brief 2026-10-17 · published 2026-10-16
02
Clinical

Personalized Cancer Vaccine Combo Is Feasible in Platinum-Sensitive Ovarian Cancer - CancerNetwork

Phase 1 NeoVax trial (NCT04024878, published in Nature Medicine) of a personalized neoantigen vaccine followed by nivolumab in platinum-sensitive high-grade epithelial ovarian cancer met its feasibility endpoint with no unexpected safety signals; 9 of 10 vaccinated patients completed all planned doses. Enrollment funnel matters for manufacturing economics: of 22 patients prescreened between November 2020 and September 2023, only 12 consented to treatment and 10 were vaccinated, with inadequate core-needle biopsy tissue the top attrition cause (n=4). Vaccination rates diverged sharply by setting — 75% of evaluable first-recurrence patients (Cohort B) versus 11% of newly diagnosed patients (Cohort A) — suggesting recurrence is the more executable indication. Common vaccine-associated AEs were injection site reactions, myalgia, chills, and neutropenia (50–70% each), with two grade 3 events reported.

news · brief 2026-10-16 · published 2026-10-15
03
Clinical

Personalized neoantigen-targeting cancer vaccines in ovarian cancer: a phase 1 trial - Nature

Nature has published a phase 1 trial of personalized neoantigen-targeting cancer vaccines in ovarian cancer. Peer-reviewed clinical data in ovarian cancer gives investors a public reference point for the modality in an indication beyond the melanoma-heavy literature that has dominated the field. Worth reading closely for how the personalized vaccine approach performed at the earliest clinical stage in this tumor type.

Melanoma
news · brief 2026-10-15 · published 2026-10-14
04
Clinical

HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors

Alaunos Therapeutics terminated its screening study (NCT05124743), the data-collection protocol that HLA-typed and somatic-mutation-profiled patients with ovarian/endometrial, colorectal, pancreatic, NSCLC, and cholangiocarcinoma tumors to match them against the company's TCR library as the entry funnel into the TCR001-201 Phase I/II autologous TCR-T study. No therapy was administered under this protocol, and patients without a TCR match were discontinued. Termination closes the screening pipeline that fed the Phase I/II study — a meaningful operational signal for a library-matching approach where match rates gate enrollment.

TCR & T-cell receptorPancreatic cancerLung cancer (NSCLC)Colorectal cancer
clinicaltrials · brief 2026-10-15 · published 2026-10-15
07
Clinical

A Single-Arm, Open-Label, Prospective Study Evaluating the Safety, Tolerability, and Immunogenicity of the NeoOVIV Vaccine in Patients With Ovarian Cancer After Surgery

[RECRUITING · PHASE1 · West China Hospital] This is a Phase I, single-arm, open-label, dose-escalation study in patients with stage II or III ovarian cancer after surgery. The study will evaluate the safety, tolerability, immune response, and preliminary clinical activity of NeoO…

clinicaltrials · brief 2026-09-25 · published 2026-09-09
08
Clinical

A Single-Arm, Open-Label, Prospective Study Evaluating the Safety, Tolerability, and Immunogenicity of the NeoOVSV Vaccine in Patients With Ovarian Cancer After Surgery

[RECRUITING · PHASE1 · West China Hospital] This is a Phase I, single-arm, open-label, prospective, non-randomized, single-center dose-escalation study. The study will evaluate the safety, tolerability, and preliminary activity of the NeoOVSV mRNA-lipid nanoparticle vaccine in pa…

mRNA vaccinesLipid nanoparticles
clinicaltrials · brief 2026-09-25 · published 2026-09-09
09
Clinical

A Single-Arm, Open-Label, Prospective Study Evaluating the Safety, Tolerability, and Immunogenicity of the NeoOVSV Vaccine in Patients With Ovarian Cancer After Surgery

West China Hospital is conducting a Phase I, single-arm dose-escalation study (NCT07724106) for NeoOVSV, an mRNA-lipid nanoparticle vaccine in stage II/III ovarian cancer. The trial evaluates safety and immunogenicity when the vaccine is administered alongside standard adjuvant chemotherapy and a PD-1 antibody. This represents an early-stage clinical evaluation of an mRNA platform in combination with checkpoint inhibition.

mRNA vaccinesLipid nanoparticles
clinicaltrials · brief 2026-07-25 · published 2026-07-23
Where nextAll topicsToday’s briefTrials tracker